Mitoxantrone structure
|
Common Name | Mitoxantrone | ||
---|---|---|---|---|
CAS Number | 65271-80-9 | Molecular Weight | 444.481 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | 805.7±65.0 °C at 760 mmHg | |
Molecular Formula | C22H28N4O6 | Melting Point | 170-174ºC | |
MSDS | N/A | Flash Point | 441.1±34.3 °C |
Use of MitoxantroneMitoxantrone is a topoisomerase II inhibitor; also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. |
Name | mitoxantrone |
---|---|
Synonym | More Synonyms |
Description | Mitoxantrone is a topoisomerase II inhibitor; also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. |
---|---|
Related Catalog | |
Target |
PKC:8.5 μM (IC50) Topoisomerase II |
In Vitro | Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its Ki value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP[1]. Treatment of B-CLL cells for 48 h with mitoxantrone (0.5 μg/mL) induces a decrease in cell viability. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of mitoxantrone is due to induction of apoptosis[2]. Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC50 values of 18 and 196 nM, respectively[3]. |
In Vivo | Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produces a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. In SC implanted Lewis lung carcinoma, mitoxantrone and ADM administered IV also shows effective antitumor activities and produces a 60% and a 45% ILS, respectively.[4]. |
Cell Assay | The human breast carcinoma cell lines MDA-MB-231 and MCF-7 are seeded in standard 96-well plates. One day after seeding, the culture medium is changed and replaced by medium containing different concentration of Mitoxantrone (10-5 to 5 μM) with or without DHA (30 μM) during 7 days. Viability of cells are measured as a whole by the tetrazolium salt assay[3]. |
Animal Admin | Mice: Mitoxantrone is tested for antitumor activity against experimental tumors in mice and the results are compared with those of seven antitumor antibiotics. The drugs are given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone is given IP at the optimal dose (1.6 mg/kg/day; as a free base)[4]. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 805.7±65.0 °C at 760 mmHg |
Melting Point | 170-174ºC |
Molecular Formula | C22H28N4O6 |
Molecular Weight | 444.481 |
Flash Point | 441.1±34.3 °C |
Exact Mass | 444.200897 |
PSA | 163.18000 |
LogP | 0.45 |
Vapour Pressure | 0.0±3.0 mmHg at 25°C |
Index of Refraction | 1.709 |
Storage condition | -20°C Freezer |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Hazard Codes | T,T+ |
---|---|
Risk Phrases | R46 |
Safety Phrases | 53-36/37/39-45-22 |
RIDADR | 3077.0 |
WGK Germany | 3 |
RTECS | CB5748500 |
Hazard Class | 9.0 |
Precursor 3 | |
---|---|
DownStream 0 |
1,4-Dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthraquinone |
mitoxanthrone |
1,4-Dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracen-9,10-dion |
UNII-BZ114NVM5P |
MFCD00242942 |
PharmasubstanceEP4 |
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyéthyl)amino]éthyl}amino)anthracène-9,10-dione |
DHAQ |
1,4-dihydroxy-5,8-bis[[2-(2-hydroxy-ethylamino)ethyl]amino]anthraquinone |
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- |
dihydroxyanthraquinone |
1,4-dehydroxy-5,8-bis[[[2-(2-hydroxyethyl)amino]ethyl]amino]-9,19-antracenedion |
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- |
MITOXANTRONUM AND THE INTERMEDIATES |
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione |
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthraquinone |
1,4-bis-[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxy-9,10-anthracenedione |
1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone |
Mitoxantrone |
[3H]-Mitoxantrone |
MITOXANTRONUM |